SCHEMBL2829918

SCHEMBL2829918

CCCCc1ccc(OS(=O)(=O)C(F)(F)F)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 3/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
HPGD P15428 2/20 0.46
ALDH1A1 P00352 2/20 0.46
HSD17B10 Q99714 1/20 0.46
STS P08842 4/20 0.44
DRD2 P14416 1/20 0.44
DRD1 P21728 1/20 0.44
DRD4 P21917 1/20 0.44
DRD5 P21918 1/20 0.44
DRD3 P35462 1/20 0.44
FAAH O00519 1/20 0.43
RARB P10826 1/20 0.42
FFAR1 O14842 1/20 0.42
FFAR4 Q5NUL3 1/20 0.42
CA1 P00915 1/20 0.42
THRB P10828 1/20 0.42
HTR1A P08908 1/20 0.41
HTR1D P28221 1/20 0.41
HTR1B P28222 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27454463 0.98 CA2 (0.47) CA2SMN1; SMN2HPGDALDH1A1HSD17B10
SCHEMBL7930478 0.95 CA2 (0.50) CA2SMN1; SMN2ALDH1A1HSD17B10STS
SCHEMBL22666338 0.94 CA2 (0.49) CA2SMN1; SMN2ALDH1A1HSD17B10STS
SCHEMBL17847695 0.90 CA2 (0.46) CA2STSDRD2DRD1DRD4
SCHEMBL8552231 0.90 RARB (0.52) CA2ALDH1A1HSD17B10STSFAAH
SCHEMBL11409736 0.86 PTGS2 (0.44) CA2SMN1; SMN2DRD2DRD1DRD4
SCHEMBL14400508 0.83 HTR1D (0.43) CA2SMN1; SMN2HPGDALDH1A1HSD17B10
SCHEMBL14062440 0.82 DRD2 (0.45) CA2SMN1; SMN2ALDH1A1STSDRD2
SCHEMBL7932239 0.82 CA2 (0.41) CA2STSCA1HTR1AHTR1D
SCHEMBL8622915 0.81 ACACB (0.42) CA2DRD2DRD1DRD4DRD5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110903316-B Phosphonate compound and preparation method and application thereof 中南大学 2021-03-02 CN claimed
CN-110903316-A Phosphonate compound and preparation method and application thereof 中南大学 2020-03-24 CN claimed
CN-110903316-B Phosphonate compound and preparation method and application thereof 中南大学 2021-03-02 CN disclosed
CN-110903316-A Phosphonate compound and preparation method and application thereof 中南大学 2020-03-24 CN disclosed
CN-101735822-B Preparation and use of low-temperature low-viscosity liquid crystal compositions UNIV WUHAN POLYTECHNIC 2015-04-29 CN disclosed
US-8981086-B2 Phosphine-ligated palladium sulfonate palladacycles MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2015-03-17 US disclosed
US-20150045570-A1 PHOSPHINE-LIGATED PALLADIUM SULFONATE PALLADACYCLES NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-02-12 US disclosed
US-8889857-B2 Phosphine-ligated palladium sulfonate palladacycles MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2014-11-18 US disclosed
US-8435387-B2 Small-scale method and apparatus for separating mixtures MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2013-05-07 US disclosed
CN-101735822-A Preparation and use of low-temperature low-viscosity liquid crystal compositions UNIV WUHAN POLYTECHNIC 2010-06-16 CN disclosed
WO-2010056331-A2 SMALL-SCALE METHOD AND APPRATUS FOR SEPARATING MIXTURES MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2010-05-20 WO disclosed
US-20100122899-A1 SMALL-SCALE METHOD AND APPARATUS FOR SEPARATING MIXTURES MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2010-05-20 US disclosed
EP-2077992-A2 INDOLE ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS Brystol-Myers Squibb Company (US) 2009-07-15 EP disclosed
WO-2008048981-A2 INDOLE ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS BRISTOL-MYERS SQUIBB COMPANY (US) 2008-04-24 WO disclosed
US-RE37087-E1 1-(4-ETHOXYPHENYL)-4-(4-FLUORO-3-PHENOXYPHENYL)-1 -TRIFLUOROMETHYLBUTANE OR 1-(4-ETHOXY-3-FLUOROPHENYL)-4-(3-PHENOXYPHENYL)-1-TRIFLUOROMETHYLBUTANE, FOR EXAMPLE; COMBATS INSECTS AND MITES SCHERING AKTIENGESELLSCHAFT (DE) 2001-03-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150045570-A1 PHOSPHINE-LIGATED PALLADIUM SULFONATE PALLADACYCLES PHOSPHO1, PDCD1, PDCD1LG2 CA2 3754/4885SMN1; SMN2 680/4885HPGD 3329/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.